A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder
Latest Information Update: 14 Jun 2019
Price :
$35 *
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 19 May 2013 Results will be presented at the American Psychiatric Association (APA) annual meeting, according to a Forest Laboratories media release.
- 10 Apr 2012 Actual patient number is 203 according to ClinicalTrials.gov.